Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS...
Pharmaceutical
Pharma Contract Manufacturing is the Quiet Reshoring Engine Investors Can’t Ignore
Black Book Flash Survey of VCs, PEs, Bankers, Analysts and Influencers Reveals Q4's Hottest Healthcare Investment NEW YORK CITY, NY...
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded...
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis...
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been...
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American...
Taiwan Showcases Smart Healthcare Breakthroughs at Taiwan Expo USA 2025
DALLAS, Aug. 31, 2025 /PRNewswire/ -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the...
AI Clinical Documentation Adoption Surges, but ROI Hinges on Governance
Largest Health Systems AI 2025 comprehensive survey to date highlights adoption momentum and governance gap in U.S. hospitals CHICAGO, IL...
Could DEA Be Next? EPA Firings Spark Questions About DEA’s Accountability in MMJ’s Marijuana Licensing Delays
After the EPA dismissed employees who publicly criticized its leadership, attention is turning to the Drug Enforcement Administration's Diversion Control...
Trimology Reviews: The Independent Expert-Backed Weight Loss Supplement That Works for Women Over 35
Why Weight Loss Feels Impossible After 35 NEW YORK CITY, NY / ACCESS Newswire / August 31, 2025 / For...
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE...
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)...
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the...
Memory Lift Reviews: Does This Supplement Improve Brain Health? Everything You Need To Know Before Buying
MIAMI, FL / ACCESS Newswire / August 30, 2025 / In today's fast-paced world, maintaining mental sharpness, focus, and memory...
Nutriessential Celebrates 20 Years of Excellence in Premium, GMP-Certified Supplements – Expands Global Reach
MIAMI BEACH, FLORIDA / ACCESS Newswire / August 30, 2025 / Nutriessential, a U.S.-based professional-grade dietary supplement provider, proudly announces...
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or...
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting...
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to...
GLG Life Tech Corporation Reports 2025 Second Quarter Financial Results
VANCOUVER, BC / ACCESS Newswire / August 29, 2025 / GLG Life Tech Corporation (TSX:GLG) ("GLG" or the "Company"), a...
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company...